US FDA Approves Limited Tobacco Products: PMTA Regulations Discussed

Dec.28.2022

The FDA approved few tobacco product applications and only from large companies with e-cigarette business, drawing controversy.

According to a report published in early December by Reagan-Udall, a limited number of tobacco product applications have been approved by the US Food and Drug Administration (FDA), and all products approved through PMTA are from large tobacco companies with electronic cigarette businesses.

Following the new regulations under PMTA, the Center for Tobacco Products (CTP) has received approximately 432 premarket applications for tobacco products. However, only a few applications have been approved, with the majority of PMTA approved products coming from large tobacco companies such as RJ Reynolds and independent e-cigarette manufacturers operating in the middle market like NJOY.

At present, the FDA is revising a controversial tobacco regulation plan due to numerous lawsuits faced by both the Center for Tobacco Products (CTP) and the entire FDA regarding public health and the tobacco industry.

In 2023, the Biden administration will be obligated to consider criticism and suggestions regarding the FDA's Center for Tobacco Products (CTP) and its policy on fairly allowing products to be released to the market.

#Products #FDA #E-cigarette Regulation #Various tobacco products #Product #Products of Tobacco

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts Observation｜VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation

2Firsts observed at Stockholm Arlanda Airport that British American Tobacco’s VELO positions the airport environment as a core marketing scenario, deploying large-format LED displays, a full flavour matrix, and clear nicotine-strength segmentation. The brand also features an instructional “How to Use VELO” section and multi-pack sales strategy, showcasing its systematic merchandising capabilities in the Nordic travel-retail channel.

Nov.19 by { "username": "", "position": "", "avatar": "", "auth": "", "seo_url": "" }

Portugal to Tax Nicotine Pouches from 2026 at €0.065 per Gram

Portugal’s 2026 State Budget adds nicotine pouches to the IEC by inserting Article 104-D into the Excise Code’s tobacco chapter. A specific duty of €0.065/g applies from 2026, with rounding to whole grams. The Budget also defines pouches (natural nicotine, up to 12 mg, tobacco-free, oral mucosal absorption). Lusa projects €1.676B in tobacco excise for 2026; combined levies near €1.993B.

Oct.30 by { "username": "", "position": "", "avatar": "", "auth": "", "seo_url": "" }

Product | Unique Serial Number + Custom Design: Vuse Launches McLaren F1 Team Limited-Edition Vape

Vuse has launched a McLaren Racing co-branded limited-edition vape, the Vuse Ultra x McLaren F1 Team Limited Edition, on its official website. Based on the standard Vuse Ultra, the device features design elements including McLaren’s “Racing Papaya” orange, and comes with wireless charging and two replaceable batteries. The product is priced at £45.

Dec.18 by { "username": "", "position": "", "avatar": "", "auth": "", "seo_url": "" }

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.

Dec.02 by { "username": "", "position": "", "avatar": "", "auth": "", "seo_url": "" }